Site Editor

Leo I. Gordon, MD, FACP

Advertisement
Advertisement

Axicabtagene Ciloleucel Outcomes in LBCL Stratified by Ethnicity and Race

By: Vanessa A. Carter, BS
Posted: Friday, July 8, 2022

Frederick L. Locke, MD, of H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, and colleagues evaluated outcomes by ethnicity and race among patients with large B-cell lymphoma (LBCL) who received axicabtagene ciloleucel. Ultimately, this treatment regimen demonstrated favorable survival and safety profiles, regardless of ethnicity and race. Their real-world outcomes were presented during the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 7571).

“No notable differences in outcomes were observed for Hispanic or Asian patients,” mentioned the study authors. “Lower response rates in African American patients...warrant further investigation including any underrepresentation not explained by a lower incidence rate for diffuse LBCL, access to care, and disease burden.”

The investigators focused on 1,389 patients with LBCL who received axicabtagene ciloleucel between October 2017 and August 2020. Participants self-reported ethnicity (Hispanic vs. non-Hispanic) and race (Black vs. White vs. Asian).

The median follow-up was 12.7 months. Most patients were White (81%), followed by Asian (6%) and Black (5%); 11% were Hispanic. Among White patients, the objective response rate was 74%, the progression-free survival rate was 48%, and the overall survival rate was 63%; the corresponding rates in Black patients were 57%, 36%, and 62%, in Asian patients were 67%, 55%, and 65%, and in Hispanic patients were 73%, 50%, and 65%, respectively.

Hispanic patients had lower rates of grade 3 or higher cytokine-release syndrome (4%) and immune effector cell–associated neurotoxicity syndrome (15%) compared with non-Hispanic patients (9% and 27%). Additionally, Black race appeared to correlate with inferior objective response and complete response rates versus White race. Furthermore, Asian patients had a more favorable duration of response than both Black and White patients. Of note, Hispanic and Asian patients demonstrated a lower risk of developing grade 3 or higher immune effector cell–associated neurotoxicity syndrome.

Disclosure: For full disclosures of the study authors, visit coi.asco.org.


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.